This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Resources to support management of prostate cancer patients

A focus on drug-to-drug interactions, managing cardiovascular risk and navigating conversations around psychosexual health.

P3 background - Article

Navigating the complexities of prostate cancer treatment requires a multifaceted approach. Our curated resources are designed to empower healthcare professionals with the knowledge and strategies needed to effectively manage drug interactions, cardiovascular risks, and psychosexual health conversations with patients.

Video Guide: Navigating Conversations Around Psychosexual Health with LGBTQ+ Individuals 

Join Consultant Andrological Surgeon, Tet Yap and Patient Representative, Dave Wardell from Out with Prostate Cancer in this on-demand video guide. Developed from discussions at the P3 Prostate Cancer Forum, this resource provides effective strategies for clinicians to address the concerns, symptoms, and side effects related to prostate cancer treatment and sexual health, particularly within the LGBTQ+ community.

Learning guides to support management of patients
P3 downloadable slide deck

At the heart of the matter: Innovative approaches to cardiovascular risk assessment and care in prostate cancer patients 

Explore our comprehensive learning guide focused on minimizing cardiovascular risks in patients receiving androgen receptor pathway inhibitors (ARPIs). This resource highlights the implications of treatment choices on cardiovascular health and emphasizes the importance of shared decision-making. Content developed by: Dr Patrick Davey, Consultant Cardiologist, Northampton General Hospital, Mr Omar El-Taji, PhD Uro-Oncology Fellow, The Christie NHS Foundation Trust and University of Manchester.

 

An Expanding Role for Pharmacists: Tackling Adverse Events and Drug-Drug Interactions

Drug-drug interactions (DDIs) are a critical concern in prostate cancer management, especially given the high prevalence of comorbidities among patients. This resource explores the evolving role of pharmacists in addressing these challenges and highlights their essential contributions to patient care. Content developed by: Dr Vikash Dodhia, Head of Pharmacy, East and North Hertfordshire NHS Trust, Diana Matthews, Advanced Oncology Pharmacist & Urology NMP, Velindre Cancer Centre.

P3 downloadable slide deck

NUBEQA  (darolutamide) Prescribing Information

Xofigo▼ (radium-223 dichloride) Prescribing Information

Exploring the mHSPC Patient Journey
Join experts for evidence-based treatment strategies on the application of triple therapy in mHSPC.
PP-NUB-GB-2382, June 2025
Finding consensus on utilising triplet therapy in mHSPC p...
Discussing triplet therapy in low-burden metastatic hormone-sensitive prostate cancer (mHSPC).
PP-NUB-GB-2383, June 2025
P3 Prostate Cancer Forum 2025
Join us as we recap the P3 Prostate Cancer Forum held on May 16-17, 2025.
PP-NUB-GB-2381, June 2025

PP-NUB-GB-2385, June 2025